SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1571434
Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1-4 mutated solid tumors
Provisionally accepted
Jiyu Huang1
Zihan Wang1
Fei Zhao1
Adilai Aisa1Shengkai Tian1
Siyuan Chen2Lianyi Peng1Xiaolu Yang1Jianxin He3,4Yue Yang1*- 1Medical College, Northwest University for Nationalities, Lanzhou, China
- 2China Medical University, Shenyang, Liaoning Province, China
- 3Gansu University of Chinese Medicine, Lanzhou, Gansu, China
- 4Key Laboratory of Dunhuang Medicine and Transformation, Gansu University of Chinese Medicine, Lanzhou, Gansu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1-4 mutated solid tumors Abstract：Objective This article aims to analyze the safety and efficacy of Erdafitinib in the treatment of patients with advanced solid tumors harboring FGFR1-4 mutations. Methods Search for relevant articles in databases such as PubMed, Embase, The Cochrane Library, Web of Science, and CNKI, covering the period from their establishment to October 25, 2024. Summarize the adverse drug reaction (AE) data, overall survival (OS), median progression-free survival (PFS), objective response rate (ORR), and other relevant data for patients with advanced solid tumors treated with Erdafitinib for FGFR1-4 mutations. Conduct a meta-analysis on the corresponding summarized data using the software Stata 18.0. Results Through our search, we identified a total of 10 articles involving 1019 patients. In urothelial carcinoma, the most prevalent adverse reactions are hyperphosphatemia (78.5%), diarrhea (56.5%), and stomatitis (51.1%). The most frequently reported adverse reactions in other solid tumors are hyperphosphatemia (66.5%), dry mouth (48.5%), and diarrhea (44.9%). Patients with urothelial carcinoma treated with Erdafitinib exhibit higher median progression-free survival (PFS) and objective response rate (ORR) compared to those treated with other solid tumor therapies. Conclusion Current evidence indicates that Erdafitinib exhibits certain therapeutic efficacy in the treatment of advanced solid tumors harboring FGFR1-4 mutations, with the most pronounced therapeutic effect observed in urothelial carcinoma. The efficacy of Erdafitinib in treating other solid tumors requires further confirmation through larger-scale studies involving a broader range of FGFR1-4 mutant tumors.
Keywords: Erdafitinib, urothelial carcinoma, FGFR1-4, tumors, Meta-analysis
Received: 05 Feb 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Huang, Wang, Zhao, Aisa, Tian, Chen, Peng, Yang, He and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yue Yang, Medical College, Northwest University for Nationalities, Lanzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.